n-methyl-3,4-methylenedioxyamphetamine and Neoplasms

n-methyl-3,4-methylenedioxyamphetamine has been researched along with Neoplasms in 3 studies

N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research

Studies (3)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Baseline STAI Trait Score

"The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.~The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive." (NCT02427568)
Timeframe: 3 months post-enrollment

Change in Beck Depression Inventory-II (BDI-II) Score From Baseline to Primary Endpoint

The Beck Depression Inventory-II (BDI-II) is a a 21-item self-reported measure of depression according to Diagnostic and Statistical Manual IV (DSM-IV) criteria. Each item is rated on a 4-point Likert scale ranging from 0 to 3. The total score is the sum of 21 items and range from 0 to 63. Score cutoffs indicate: 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, and 29-63 severe depression. Higher scores indicate more severe depressive symptoms. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Change in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint

The Global Assessment of Function (GAF) is a measure of a person's global social functioning made through clinical observation. The GAF consists of a single score, with scores ranging from 0 to 100, with 100 reflecting superior function and zero reflecting serious risk of causing harm to the self or others. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post 2nd experimental session)

Change in MADRS Score From Baseline to Primary Endpoint

The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item, clinician administered questionnaire used to diagnose the severity of depressive episodes. Each item has a score of 0 to 6. Overall scores are summed and range from 0 to 60. Score cutoffs indicate: 0-6 normal/symptom absent, 7-19 mild depression, 20-34 moderate depression, > 34 severe depression. Higher scores indicate greater severe depression. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Change in Pittsburgh Sleep Quality Inventory (PSQI) From Baseline to Primary Endpoint

The Pittsburgh Sleep Quality Index (PSQI) is a measure of self-reported sleep quality over a one month period. It consists of 19 items with possible responses ranging from zero to four on a five-point scale. The PSQI consists of seven sub-scales: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medications, and daytime dysfunction. These are all summed to produce a single global scale. Global scores can range from 0 to 21, with higher scores reflecting poorer sleep quality, and a score below 5 indicating good sleep quality. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Change in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint

The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales; relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Questions are answered on a scale from 0 (I did not experience this change) to 5 (I experienced this change to a great degree). Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Change in Self-Compassion Scale (SCS) From Baseline to Primary Endpoint

"The Self-Compassion Scale (SCS) is a 26-item self-reported questionnaire that assesses how respondents relate to themselves and treat themselves during difficult or painful experiences. Items are scored along a 5-point Likert-type scale ranging from 1 almost never to 5 almost always. The SCS has six component (subscale) scores: self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification. Subscale scores are calculated by computing the mean of subscale item responses.~A total self-compassion score is calculated by the sum of the subscale scores and range from 24 to 120 with higher scores indicating greater self compassion. Higher scores have been found to correlate with positive mental health outcomes, as well as decreased depression and anxiety." (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Change in STAI State Score From Baseline to Primary Endpoint

"The state subscale of the STAI (STAI-S) is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Like the trait subscale, participants respond to each item on the state subscale by selecting a response from a 4-point Likert scale ranging from 4 (Not at all) to 1 (Very much so), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.~The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive." (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Change in State Trait Anxiety Inventory (STAI) Trait Score From Baseline to Primary Endpoint

"The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.~The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The use of the trait subscale as the primary outcome measure was intended to target those anxiety symptoms that are chronic and pervasive." (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Primary Endpoint STAI Trait Score

"The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.~The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive." (NCT02427568)
Timeframe: One month post-2nd experimental session

Change in Death Attitudes Profile (DAP) From Baseline to Primary Endpoint

"The Death Attitudes Profile (DAP) is a 32-item self-reported questionnaire that assesses individual attitudes and beliefs about death and dying. Each item on the scale is rated along a 7-point Likert scale ranging from strongly disagree (score of 1) to strongly agree (score of 7), with higher scores indicating more positive attitudes toward death.~The DAP consists of 5 dimensions: fear of death (7 items summed with total scores ranging from 7 to 49), death avoidance (5 items summed with total scores ranging from 5 to 35), neutral acceptance (5 items summed with total scores ranging from 5 to 35), approach acceptance (10 items summed with total scores ranging from 10 to 70), and escape acceptance (5 items summed with total scores ranging from 5 to 35). For each dimension, a mean scale score can be computed by dividing the total scale score by the number of items forming each scale." (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Change in Functional Assessment of Chronic Illness Therapy Scale (FACIT) From Baseline to Primary Endpoint

The Functional Assessment of Chronic Illness Therapy Scale (FACIT-Sp) is a 27-item self-report measure of quality of life issues specifically relevant to individuals with a chronic or life-threatening illness or condition. The core questionnaire consists of four subscales: Physical Well-being, Social/Family Well-being, Emotional Well-being, and Functional Well-being. Responses range from 0 (not at all) to 4 (very much), with higher scores indicating greater well-being. For each subscale, total scores were summed and range from 0 to 16. (NCT02427568)
Timeframe: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Reviews

1 review available for n-methyl-3,4-methylenedioxyamphetamine and Neoplasms

Trials

1 trial available for n-methyl-3,4-methylenedioxyamphetamine and Neoplasms

Other Studies

1 other study available for n-methyl-3,4-methylenedioxyamphetamine and Neoplasms